Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONWARDS 4 trial of once-weekly insulin icodec versus once-daily insulin glargine in basal-bolus treated type 2 diabetes
jRCT2031210076Completed
- Sponsor
- Novo Nordisk
- Start
- May 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Randomised, open-label trial of insulin icodec, insulin glargine and insulin aspart in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change from baseline in HbA1c at Week 26. Started May 2021; status: completed.
02
Drugs
insulin icodecinsulin glargineinsulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2031210076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210076.